New Zealand Prime Minister Jacinda Ardern receiving her first Pfizer/BioNTech dose, June 18 (Alex Burton/NZ Herald via AP Images)

June 21, 2021 07:46 AM EDTUpdated 11:11 AM

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12

Nicole DeFeudis

Editor

Josh Sullivan

A few weeks after snagging an emergency use authorization for their monoclonal antibody sotrovimab based on interim data, GSK and Vir Biotechnology are back with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12

Nicole DeFeudis

Editor

Josh Sullivan

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Covid-19 roundup: Af­ter win­ning an EUA, GSK and Vir are back with full da­ta on their mon­o­clon­al an­ti­body; New Zealand au­tho­rizes Pfiz­er/BioN­Tech vac­cine for kids as young as 12

Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12